BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. Its lead program, BMD-001, shows disease-modifying potential for the treatment of neurodegenerative diseases by targeting a specific miRNA. BIORCHESTRA has been selected as the first awardee of J&J’s Innovation QuickFire Challenge on Neuroscience in June 2021. For more information, visit BIORCHESTRA’s website at http://biorchestra.com/.